^
^
CRESTOR print advertising – Andi
^
CRESTOR print advertising – Bryan
^
CRESTOR print advertising
 
Close popup
CRESTOR® (rosuvastatin calcium)



 

Lowering LDL Cholesterol in Patients Starting Therapy

In this section, you can review LDL-C reduction results and LDL-C goal attainment results from clinical trials in which CRESTOR® (rosuvastatin calcium) was used as an adjunct to diet in patients starting statin therapy. You can also download the STELLAR publication.

LDL Cholesterol Reductions vs Other Statins

  • LDL-C reductions vs atorvastatin in patients with CHD, CHD risk equivalents, or clinical evidence of atherosclerosis1 Adapted from the ECLIPSE Trial
  • > View Chart
  • LDL-C reductions vs atorvastatin in patients with cardiovascular disease (CVD) and low HDL-C2 Adapted from the RADAR Trial
  • > View Chart
  • LDL-C reductions vs atorvastatin in patients with hyperlipidemia or mixed dyslipidemia3 Adapted from the STELLAR Trial
  • > View Chart
  • LDL-C reductions vs simvastatin in patients with hyperlipidemia or mixed dyslipidemia3 Adapted from the STELLAR Trial
  • > View Chart
  • LDL-C reductions vs pravastatin in patients with hyperlipidemia or mixed dyslipidemia3 Adapted from the STELLAR Trial
  • > View Chart

LDL Cholesterol Goal Attainment vs Other Statins

  • NCEP ATP III Guideline Goal attainment (LDL-C <100 mg/dL) vs atorvastatin in patients with CHD, CHD risk equivalents, or clinical evidence of atherosclerosis1 Adapted from the ECLIPSE Trial
  • > View Chart
  • Goal attainment (LDL-C <100 mg/dL) vs atorvastatin in patients with hyperlipidemia or mixed dyslipidemia4 Adapted from the STELLAR Trial
  • > View Chart
  • Goal attainment (LDL-C <100 mg/dL) vs simvastatin in patients with hyperlipidemia or mixed dyslipidemia4 Adapted from the STELLAR Trial
  • > View Chart
  • Goal attainment (LDL-C <100 mg/dL) vs pravastatin in patients with hyperlipidemia or mixed dyslipidemia4 Adapted from the STELLAR Trial
  • > View Chart
TRIAL: ECLIPSE
^ Back to top

LDL-C reductions vs atorvastatin in patients with CHD, CHD risk equivalents, or clinical evidence of atherosclerosis1

LDL Cholesterol reductions vs. atorvastatin in patients with CHD

*P<.001 CRESTOR 10 mg vs atorvastatin 10 mg; CRESTOR 20 mg vs atorvastatin 20 mg; CRESTOR 40 mg vs atorvastatin 40 mg; CRESTOR 40 mg vs atorvastatin 80 mg.

Mean baseline LDL-C: 188 mg/dL to 189 mg/dL (all arms of trial).

Week 6:
CRESTOR 10 mg n=498
atorvastatin 10 mg n=510

Week 12:
CRESTOR 20 mg n=492
atorvastatin 20 mg n=494

Week 18:
CRESTOR 40 mg n=480
atorvastatin 40 mg n=483

Week 24:
CRESTOR 40 mg n=464
atorvastatin 80 mg n=476

Enlarge Chart
Show/Hide Description

ECLIPSE was a 24-week, open-label, randomized, multicenter, forced-titration, parallel-group trial comparing the efficacy and safety of CRESTOR and atorvastatin in patients with hypercholesterolemia and CHD, CHD risk equivalents (10-year risk >20%), or clinical evidence of atherosclerosis. Following a 6-week dietary lead-in period, patients were randomized to receive CRESTOR 10 mg or atorvastatin 10 mg for 6 weeks. Doses were force-titrated at 6-week intervals until maximum doses were achieved. Statistical comparisons were not made across the dose range, only across the same time period. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal at week 24. Percentage change from baseline in HDL-C was a secondary end point.1

TRIAL: RADAR
^ Back to top

LDL-C reductions vs atorvastatin in patients with cardiovascular disease (CVD) and low HDL-C2

LDL Cholesterol reductions vs. atorvastatin in patients with CVD

*P<.05 CRESTOR 10 mg vs atorvastatin 20 mg.
†P<.01 CRESTOR 20 mg vs atorvastatin 40 mg.
‡P<.0001 CRESTOR 40 mg vs atorvastatin 80 mg.

Mean baseline LDL-C: 139 mg/dL to 143 mg/dL.

CRESTOR n=230
atorvastatin n=231

Enlarge Chart
Show/Hide Description

RADAR was a randomized, multicenter, open-label, parallel-group, forced-titration trial comparing the efficacy and safety of CRESTOR with atorvastatin in hypercholesterolemic patients with CVD and low HDL-C levels (<40 mg/dL). Patients were randomized to receive CRESTOR 10 mg or atorvastatin 20 mg for 6 weeks. At week 6, doses were increased to CRESTOR 20 mg or atorvastatin 40 mg, and at week 12, doses were increased to CRESTOR 40 mg or atorvastatin 80 mg for a further 6 weeks. Statistical comparisons were not made across the dose range, only across the same time period (6 weeks vs 6 weeks, 12 weeks vs 12 weeks, 18 weeks vs 18 weeks). The primary end point of RADAR was the percentage change from baseline in LDL-C/HDL-C ratio at 6 weeks.2

TRIAL: STELLAR
^ Back to top

LDL-C reductions vs atorvastatin in patients with hyperlipidemia or mixed dyslipidemia3

LDL Cholesterol reductions vs. atorvastatin in patients with hyperlipidemia or mixed dyslipidemia

*P<.002 CRESTOR 10 mg vs atorvastatin 10 mg.
†P<.002 CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg.
‡P<.002 CRESTOR 40 mg vs atorvastatin 40 mg.

Mean baseline LDL-C: 187 mg/dL to 194 mg/dL (all arms of trial).

CRESTOR n=473
atorvastatin n=634

Enlarge Chart
Download Trial
Show/Hide Description

STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at week 6. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg.3

TRIAL: STELLAR
^ Back to top

LDL-C reductions vs simvastatin in patients with hyperlipidemia or mixed dyslipidemia3

LDL Cholesterol reductions vs. simvastatin in patients with hyperlipidemia or mixed dyslipidemia

*P<.002 CRESTOR 10 mg vs simvastatin 10 mg, 20 mg, 40 mg.
†P<.002 CRESTOR 20 mg vs simvastatin 20 mg, 40 mg, 80 mg.
‡P<.002 CRESTOR 40 mg vs simvastatin 40 mg, 80 mg.

Mean baseline LDL-C: 187 mg/dL to 194 mg/dL (all arms of trial).

CRESTOR n=473
simvastatin n=648

Enlarge Chart
Download Trial
Show/Hide Description

STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at week 6. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg.3

TRIAL: STELLAR
^ Back to top

LDL-C reductions vs pravastatin in patients with hyperlipidemia or mixed dyslipidemia3

LDL Cholesterol reductions vs. simvastatin in patients with hyperlipidemia or mixed dyslipidemia

*P<.002 CRESTOR 10 mg vs pravastatin 10 mg, 20 mg, 40 mg.
†P<.002 CRESTOR 20 mg vs pravastatin 20 mg, 40 mg.
‡P<.002 CRESTOR 40 mg vs pravastatin 40 mg.

Mean baseline LDL-C: 187 mg/dL to 194 mg/dL (all arms of trial).

CRESTOR n=473
pravastatin n=485

Enlarge Chart
Download Trial
Show/Hide Description

STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at week 6. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg.3

TRIAL: ECLIPSE
^ Back to top

NCEP ATP III Guideline Goal attainment (LDL-C <100 mg/dL) vs atorvastatin in patients with CHD, CHD risk equivalents, or clinical evidence of atherosclerosis1

LDL Cholesterol goal attainment vs. atorvastatin in patients with CHD

†P<.001 CRESTOR 10 mg vs atorvastatin 10 mg; CRESTOR 20 mg vs atorvastatin 20 mg; CRESTOR 40 mg vs atorvastatin 40 mg; CRESTOR 40 mg vs atorvastatin 80 mg.

Mean baseline LDL-C: 188 mg/dL to 189 mg/dL (all arms of trial).

Week 6:
CRESTOR 10 mg n=498
atorvastatin 10 mg n=510

Week 12:
CRESTOR 20 mg n=492
atorvastatin 20 mg n=494

Week 18:
CRESTOR 40 mg n=480
atorvastatin 40 mg n=483

Week 24:
CRESTOR 40 mg n=464
atorvastatin 80 mg n=476

According to the NCEP ATP III Guidelines, the LDL-C goal for 0 to 1 risk factors is <160 mg/dL, 2+ risk factors (10-year risk <20%) is <130 mg/dL, and CHD or CHD risk equivalents (10-year risk >20%) is <100 mg/dL.5

Enlarge Chart
Show/Hide Description

ECLIPSE was a 24-week, open-label, randomized, multicenter, forced-titration, parallel-group trial comparing the efficacy and safety of CRESTOR and atorvastatin in patients with hypercholesterolemia and CHD, CHD risk equivalents (10-year risk >20%), or clinical evidence of atherosclerosis. Following a 6-week dietary lead-in period, patients were randomized to receive CRESTOR 10 mg or atorvastatin 10 mg for 6 weeks. Doses were force-titrated at 6-week intervals until maximum doses were achieved. Statistical comparisons were not made across the dose range, only across the same time period. The primary end point was percentage of patients achieving NCEP ATP III LDL-C goal at week 24. Percentage change from baseline in HDL-C was a secondary end point.1

TRIAL: STELLAR
^ Back to top

Goal attainment (LDL-C <100 mg/dL) vs atorvastatin in patients with hyperlipidemia or mixed dyslipidemia4

LDL Cholesterol goal attainment vs. atorvastatin in patients with hyperlipidemia or mixed dyslipidemia

*P<.002 CRESTOR 10 mg vs atorvastatin 10 mg.
†P<.002 CRESTOR 20 mg vs atorvastatin 20 mg.
‡P<.002 CRESTOR 40 mg vs atorvastatin 40 mg.

Mean baseline LDL-C: 187 mg/dL to 194 mg/dL3

CRESTOR 10 mg n=156
CRESTOR 20 mg n=160
CRESTOR 40 mg n=157

atorvastatin 10 mg n=158
atorvastatin 20 mg n=154
atorvastatin 40 mg n=156
atorvastatin 80 mg n=165

Enlarge Chart
Download Trial
Show/Hide Description

STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at week 6. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg.3

TRIAL: STELLAR
^ Back to top

Goal attainment (LDL-C <100 mg/dL) vs simvastatin in patients with hyperlipidemia or mixed dyslipidemia4

LDL Cholesterol goal attainment vs. simvastatin in patients with hyperlipidemia or mixed dyslipidemia

*P<.002 CRESTOR 10 mg vs simvastatin 10 mg, 20 mg, 40 mg.
†P<.002 CRESTOR 20 mg vs simvastatin 20 mg, 40 mg, 80 mg.
‡P<.002 CRESTOR 40 mg vs simvastatin 40 mg, 80 mg.

Mean baseline LDL-C: 187 mg/dL to 194 mg/dL (all arms of trial).3

CRESTOR 10 mg n=156
CRESTOR 20 mg n=160
CRESTOR 40 mg n=157

simvastatin 10 mg n=165
simvastatin 20 mg n=162
simvastatin 40 mg n=158
simvastatin 80 mg n=163

Enlarge Chart
Download Trial
Show/Hide Description

STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at week 6. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg.3

TRIAL: STELLAR
^ Back to top

Goal attainment (LDL-C <100 mg/dL) vs pravastatin in patients with hyperlipidemia or mixed dyslipidemia4

LDL Cholesterol goal attainment vs. simvastatin in patients with hyperlipidemia or mixed dyslipidemia

*P<.002 CRESTOR 10 mg vs pravastatin 10 mg, 20 mg, 40 mg.
†P<.002 CRESTOR 20 mg vs pravastatin 20 mg, 40 mg.
‡P<.002 CRESTOR 40 mg vs pravastatin 40 mg.

Mean baseline LDL-C: 187 mg/dL to 194 mg/dL (all arms of trial).3

CRESTOR 10 mg n=156
CRESTOR 20 mg n=160
CRESTOR 40 mg n=157

pravastatin 10 mg n=160
pravastatin 20 mg n=164
pravastatin 40 mg n=161

Enlarge Chart
Download Trial
Show/Hide Description

STELLAR was a 6-week, multicenter, open-label, randomized, 15-arm trial comparing the efficacy and safety of CRESTOR with atorvastatin, simvastatin, and pravastatin in 2240 patients with hyperlipidemia or mixed dyslipidemia. The primary end point was percentage change from baseline in LDL-C at week 6. The study performed the following dose comparisons: CRESTOR 10 mg vs atorvastatin 10 mg, 20 mg, and 40 mg, simvastatin 10 mg, 20 mg, and 40 mg, and pravastatin 10 mg, 20 mg, and 40 mg; CRESTOR 20 mg vs atorvastatin 20 mg, 40 mg, and 80 mg, simvastatin 20 mg, 40 mg, and 80 mg, and pravastatin 20 mg and 40 mg; and CRESTOR 40 mg vs atorvastatin 40 mg and 80 mg, simvastatin 40 mg and 80 mg, and pravastatin 40 mg.3